DEVYSER DIAGNOSTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.6 SEK | -0.43% |
|
-5.26% | +19.08% |
| Apr. 25 | Devyser Receives IVDR Approval for Post-Transplant Monitoring Software | CI |
| Apr. 23 | Devyser Diagnostics AB Enters into Co-Marketing Agreement with Hamilton Bonaduz AG | CI |
Presentation Operator MessageOperator (Operator)Welcome to the Devyser Diagnostics Q2 Report 2...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnosticsâ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
59.91
DKK
Average target price
80.73
DKK
Spread / Average Target
+34.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.08% | 141M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +47.07% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- DVYSR Stock
- News Devyser Diagnostics AB
- Transcript : Devyser Diagnostics AB, Q2 2023 Earnings Call, Aug 23, 2023